AstraZeneca Historical Balance Sheet

0A4J Stock

67.09 0.93 1.41%

Trend analysis of AstraZeneca PLC ADR balance sheet accounts such as Short Long Term Debt Total of 18 B, Total Current Liabilities of 21.3 B or Total Stockholder Equity of 11.4 B provides information on AstraZeneca PLC's total assets, liabilities, and equity, which is the actual value of AstraZeneca PLC ADR to its prevalent stockholders. By breaking down trends over time using AstraZeneca PLC balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining AstraZeneca PLC ADR latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AstraZeneca PLC ADR is a good buy for the upcoming year.

AstraZeneca PLC Inventory

4.58 Billion

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About AstraZeneca Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of AstraZeneca PLC ADR at a specified time, usually calculated after every quarter, six months, or one year. AstraZeneca PLC Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of AstraZeneca PLC and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which AstraZeneca currently owns. An asset can also be divided into two categories, current and non-current.

AstraZeneca PLC Balance Sheet Chart

At this time, AstraZeneca PLC's Retained Earnings are comparatively stable compared to the past year. Other Current Liabilities is likely to gain to about 5 B in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 18 B in 2024.

Total Assets Short Long Term Debt Total Total Current Liabilities Total Stockholder Equity

Total Assets

Total assets refers to the total amount of AstraZeneca PLC assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in AstraZeneca PLC ADR books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on AstraZeneca PLC balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of AstraZeneca PLC ADR are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most accounts from AstraZeneca PLC's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into AstraZeneca PLC ADR current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2019	2020	2023	2024 (projected)
Short and Long Term Debt Total	16.2B	18.0B	20.7B	18.0B
Total Assets	61.4B	66.7B	76.7B	69.2B

Short Long Term Debt Total Total Assets

AstraZeneca PLC balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Cash	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Short Term Investments	Capital Surpluse	Inventory	Other Current Assets	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Other Current Liab	Other Liab	Net Tangible Assets	Accounts Payable	Other Stockholder Equity
Total Assets		0.83	0.9	-0.08	-0.71	0.77	0.68	0.83	0.82	0.82	0.92	-0.78	0.73	0.61	0.2	0.98	0.81	0.79	-0.67	0.92	0.85	0.28	-0.73	-0.39	0.8	-0.7
Short Long Term Debt Total	0.83		0.92	-0.25	-0.91	0.79	0.91	1.0	0.82	0.94	0.76	-0.83	0.86	0.73	0.61	0.9	0.91	0.94	-0.93	0.87	0.94	0.3	-0.84	-0.04	0.48	-0.81
Total Current Liabilities	0.9	0.92		-0.03	-0.91	0.87	0.83	0.9	0.9	0.98	0.76	-0.84	0.89	0.72	0.38	0.92	0.93	0.92	-0.81	0.96	0.95	0.17	-0.83	-0.18	0.68	-0.86
Total Stockholder Equity	-0.08	-0.25	-0.03		0.19	0.19	-0.11	-0.28	0.14	-0.06	-0.42	0.05	-0.01	0.08	-0.46	-0.22	0.01	0.09	0.43	-0.1	-0.1	-0.06	0.42	0.3	0.37	0.44
Retained Earnings	-0.71	-0.91	-0.91	0.19		-0.79	-0.92	-0.89	-0.81	-0.95	-0.6	0.83	-0.94	-0.8	-0.5	-0.78	-0.92	-0.9	0.94	-0.86	-0.96	-0.27	0.81	0.0	-0.44	0.87
Cash	0.77	0.79	0.87	0.19	-0.79		0.69	0.75	1.0	0.81	0.54	-0.9	0.87	0.71	0.27	0.77	0.89	0.87	-0.69	0.82	0.84	0.35	-0.65	0.07	0.66	-0.62
Other Assets	0.68	0.91	0.83	-0.11	-0.92	0.69		0.89	0.71	0.9	0.55	-0.76	0.87	0.85	0.5	0.74	0.89	0.93	-0.91	0.76	0.94	0.39	-0.67	0.08	0.45	-0.7
Long Term Debt	0.83	1.0	0.9	-0.28	-0.89	0.75	0.89		0.79	0.92	0.77	-0.81	0.82	0.71	0.64	0.9	0.89	0.92	-0.92	0.86	0.92	0.26	-0.83	-0.08	0.47	-0.81
Cash And Short Term Investments	0.82	0.82	0.9	0.14	-0.81	1.0	0.71	0.79		0.84	0.61	-0.91	0.88	0.72	0.28	0.82	0.91	0.88	-0.71	0.85	0.86	0.35	-0.69	0.01	0.68	-0.65
Net Receivables	0.82	0.94	0.98	-0.06	-0.95	0.81	0.9	0.92	0.84		0.69	-0.81	0.88	0.8	0.5	0.86	0.95	0.94	-0.86	0.94	0.97	0.13	-0.79	-0.13	0.6	-0.86
Good Will	0.92	0.76	0.76	-0.42	-0.6	0.54	0.55	0.77	0.61	0.69		-0.61	0.56	0.42	0.27	0.94	0.64	0.59	-0.64	0.83	0.72	0.2	-0.74	-0.54	0.59	-0.72
Short Term Investments	-0.78	-0.83	-0.84	0.05	0.83	-0.9	-0.76	-0.81	-0.91	-0.81	-0.61		-0.82	-0.76	-0.36	-0.79	-0.91	-0.86	0.81	-0.8	-0.87	-0.44	0.72	0.07	-0.64	0.73
Capital Surpluse	0.73	0.86	0.89	-0.01	-0.94	0.87	0.87	0.82	0.88	0.88	0.56	-0.82		0.74	0.26	0.77	0.88	0.9	-0.87	0.8	0.93	0.49	-0.76	0.17	0.47	-0.72
Inventory	0.61	0.73	0.72	0.08	-0.8	0.71	0.85	0.71	0.72	0.8	0.42	-0.76	0.74		0.43	0.62	0.91	0.8	-0.7	0.76	0.86	0.24	-0.36	-0.12	0.65	-0.54
Other Current Assets	0.2	0.61	0.38	-0.46	-0.5	0.27	0.5	0.64	0.28	0.5	0.27	-0.36	0.26	0.43		0.34	0.48	0.45	-0.59	0.38	0.42	-0.25	-0.41	-0.03	-0.08	-0.52
Total Liab	0.98	0.9	0.92	-0.22	-0.78	0.77	0.74	0.9	0.82	0.86	0.94	-0.79	0.77	0.62	0.34		0.84	0.82	-0.78	0.93	0.89	0.29	-0.81	-0.34	0.69	-0.78
Total Current Assets	0.81	0.91	0.93	0.01	-0.92	0.89	0.89	0.89	0.91	0.95	0.64	-0.91	0.88	0.91	0.48	0.84		0.94	-0.83	0.92	0.97	0.25	-0.67	-0.12	0.69	-0.76
Short Term Debt	0.79	0.94	0.92	0.09	-0.9	0.87	0.93	0.92	0.88	0.94	0.59	-0.86	0.9	0.8	0.45	0.82	0.94		-0.84	0.83	0.95	0.34	-0.72	0.1	0.59	-0.69
Intangible Assets	-0.67	-0.93	-0.81	0.43	0.94	-0.69	-0.91	-0.92	-0.71	-0.86	-0.64	0.81	-0.87	-0.7	-0.59	-0.78	-0.83	-0.84		-0.75	-0.9	-0.42	0.85	-0.06	-0.27	0.84
Common Stock	0.92	0.87	0.96	-0.1	-0.86	0.82	0.76	0.86	0.85	0.94	0.83	-0.8	0.8	0.76	0.38	0.93	0.92	0.83	-0.75		0.92	0.08	-0.75	-0.39	0.75	-0.84
Property Plant Equipment	0.85	0.94	0.95	-0.1	-0.96	0.84	0.94	0.92	0.86	0.97	0.72	-0.87	0.93	0.86	0.42	0.89	0.97	0.95	-0.9	0.92		0.35	-0.76	-0.1	0.63	-0.8
Other Current Liab	0.28	0.3	0.17	-0.06	-0.27	0.35	0.39	0.26	0.35	0.13	0.2	-0.44	0.49	0.24	-0.25	0.29	0.25	0.34	-0.42	0.08	0.35		-0.25	0.41	0.1	-0.01
Other Liab	-0.73	-0.84	-0.83	0.42	0.81	-0.65	-0.67	-0.83	-0.69	-0.79	-0.74	0.72	-0.76	-0.36	-0.41	-0.81	-0.67	-0.72	0.85	-0.75	-0.76	-0.25		0.07	-0.26	0.91
Net Tangible Assets	-0.39	-0.04	-0.18	0.3	0.0	0.07	0.08	-0.08	0.01	-0.13	-0.54	0.07	0.17	-0.12	-0.03	-0.34	-0.12	0.1	-0.06	-0.39	-0.1	0.41	0.07		-0.5	0.31
Accounts Payable	0.8	0.48	0.68	0.37	-0.44	0.66	0.45	0.47	0.68	0.6	0.59	-0.64	0.47	0.65	-0.08	0.69	0.69	0.59	-0.27	0.75	0.63	0.1	-0.26	-0.5		-0.37
Other Stockholder Equity	-0.7	-0.81	-0.86	0.44	0.87	-0.62	-0.7	-0.81	-0.65	-0.86	-0.72	0.73	-0.72	-0.54	-0.52	-0.78	-0.76	-0.69	0.84	-0.84	-0.8	-0.01	0.91	0.31	-0.37

Click cells to compare fundamentals

AstraZeneca PLC Account Relationship Matchups

AstraZeneca PLC balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	63.4B	60.7B	61.4B	66.7B	76.7B	69.2B
Short Long Term Debt Total	15.6B	17.4B	16.2B	18.0B	20.7B	18.0B
Total Current Liabilities	18.1B	20.3B	22.6B	26.3B	30.2B	21.3B
Total Stockholder Equity	15.0B	12.5B	13.1B	15.6B	14.1B	11.4B
Retained Earnings	5.0B	6.4B	3.6B	3.1B	2.8B	5.2B
Cash	2.5B	3.9B	4.6B	6.7B	7.6B	4.8B
Other Assets	3.5B	4.3B	5.3B	4.2B	4.8B	3.9B
Long Term Debt	15.6B	17.4B	15.7B	17.5B	20.1B	17.7B
Cash And Short Term Investments	4.6B	5.7B	6.2B	8.0B	9.2B	6.7B
Net Receivables	5.2B	5.7B	8.8B	9.9B	11.4B	6.5B
Good Will	11.8B	11.7B	11.7B	11.8B	13.6B	12.9B
Capital Surpluse	4.4B	4.4B	7.9B	8.0B	9.2B	6.4B
Inventory	3.2B	4.0B	9.0B	4.7B	5.4B	4.6B
Other Current Assets	106M	99M	556M	398M	457.7M	385.6M
Total Liab	48.4B	48.2B	48.3B	51.1B	58.8B	53.6B
Total Current Assets	15.6B	19.5B	26.2B	22.6B	26.0B	19.8B
Short Term Debt	152M	160M	146M	286M	328.9M	184.4M
Intangible Assets	26.2B	22.0B	20.8B	20.9B	18.9B	18.8B
Property Plant Equipment	8.3B	8.9B	10.2B	9.4B	10.9B	9.2B
Other Current Liab	4.9B	5.8B	4.5B	3.8B	4.4B	5.0B
Other Liab	10.3B	10.5B	13.0B	8.5B	7.6B	8.8B
Net Tangible Assets	(19.4B)	(17.2B)	(23.1B)	(22.1B)	(25.4B)	(26.7B)
Accounts Payable	1.8B	2.4B	2.8B	2.6B	2.9B	2.5B
Other Stockholder Equity	(143M)	881M	111M	(1.6B)	(1.5B)	(1.4B)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for AstraZeneca Stock Analysis

When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC